Clinical BenefitsData from BioMarin’s ongoing CANOPY trial shows improvements in health-related quality of life and bone length while maintaining bone strength.
Market OpportunityTransCon CNP had statistically significant improvement in Annualized Growth Velocity compared to placebo, with safety generally well-tolerated and no study discontinuations.
Stock ValuationCurrent price creates a unique opportunity to buy the dip and can attract M&A interest, with shares looking meaningfully undervalued and not reflecting market growth from new indications.